Paul B. Manning - 23 Feb 2026 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Director
Signature
/s/ Charles Schoch, as Attorney-In-Fact for Paul B. Manning
Issuer symbol
CADL
Transactions as of
23 Feb 2026
Net transactions value
+$2,999,996
Form type
4
Filing time
26 Feb 2026, 19:38:59 UTC
Previous filing
12 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Manning Paul B Director C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM /s/ Charles Schoch, as Attorney-In-Fact for Paul B. Manning 26 Feb 2026 0001494695

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CADL Common Stock Purchase $2,999,996 +550,458 +25% $5.45 2,763,527 23 Feb 2026 By Paul B. Manning Revocable Trust F1
holding CADL Common Stock 1,303,752 23 Feb 2026 By BKB Growth Investments, LLC F2
holding CADL Common Stock 1,681,000 23 Feb 2026 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F2 The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F3 Includes shares held jointly with spouse.